Patent intelligence · US
US 12371333
Purification of clinoptilolite
Purification of clinoptilolite
Patent details — US 12371333
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jul 29, 2025
- Expiration
- Jul 24, 2045
- Applicant
- Revelation Health LLC
- Claims
- 12
- CPC classes
- A61K, A61K33/06, A61K9/127, A61P
Quick answer
US 12371333 (Purification of clinoptilolite) is held by Revelation Health LLC. Status: granted. Granted Jul 29, 2025. Expires Jul 24, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Revelation Health LLC
- Grant date
- Expiration
- Claims
- 12
- CPC classes
- A61K, A61K33/06, A61K9/127, A61P, A61P39/06
More from Revelation Health LLC
Related pharmaceutical patents in our USPTO index.
Frequently asked questions
What is US patent 12371333?
US 12371333 (Purification of clinoptilolite) is held by Revelation Health LLC. Status: granted. Granted Jul 29, 2025. Expires Jul 24, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12371333?
Revelation Health LLC is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 2 pharmaceutical patents for this assignee.
When does US 12371333 expire?
Our index shows an expiration date of Jul 24, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.